RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:289596

Juvenile nasopharyngeal angiofibroma

low confidenceDisorder

Also known as: JNA

Publications

1,581

Trials

1

Interventional, condition-specific

Researchers

1,004

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Juvenile nasopharyngeal angiofibroma (JNA) is a rare and benign but locally aggressive fibrovascular tumor arising from the posterolateral wall of the nasopharynx, which affects mainly young and adolescent males (onset usually occurring between 7-19 years of age) and that presents as a mass in the nasopharynx and nasal cavity, leading to manifestations such as nasal obstruction, epistaxis, profound facial swelling, proptosis or diplopia. Although slowly , it has a high rate of recurrence and sometimes invades adjacent structures.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

juvenile nasopharyngeal angiofibroma · juvenile nasopharyngeal angiofibroma (disease) · nasopharyngeal angiofibroma · nasopharyngeal juvenile angiofibroma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,581 matched papers (610 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,581

1,581 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,581 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

610 in the last 10 years · low confidence

Phrase hits: 1,581 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,004

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Kumar R13 papers · 2024

    Department of Nuclear Medicine.

    Papers in Europe PMC
  2. 02
    Bhalla AS8 papers · 2024

    Department of Radiology, All India Institute of Medical Sciences, New Delhi, India.

    Papers in Europe PMC
  3. 03
    Liu Q7 papers · 2025

    Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.

    Papers in Europe PMC
  4. 04
    Thakar A7 papers · 2024

    Department of Otorhinolaryngology and Head and Neck Surgery.

    Papers in Europe PMC
  5. 05
    Mishra A6 papers · 2025

    Department of Otorhinolaryngology and Head and Neck Surgery, King George's Medical University, Lucknow, India. Electronic address: amishra_ent@yahoo.com.

    Papers in Europe PMC
  6. 06
    Sakthivel P6 papers · 2021

    Department of Otorhinolaryngology and Head and Neck Surgery.

    Papers in Europe PMC
  7. 07
    Wang D6 papers · 2025

    Department of Otolaryngology-Head and Neck Surgery, Affiliated Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, People's Republic of China.

    Papers in Europe PMC
  8. 08
    Li H5 papers · 2025

    Department of Otolaryngology-Head and Neck Surgery, Affiliated Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, People's Republic of China.

    Papers in Europe PMC
  9. 09
    Mishra SC5 papers · 2025

    Department of Otorhinolaryngology and Head and Neck Surgery, King George's Medical University, Lucknow, India.

    Papers in Europe PMC
  10. 10
    Sun X5 papers · 2025

    Department of Otolaryngology-Head and Neck Surgery, Affiliated Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, People's Republic of China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; 1 currently recruiting in our sample.

Data as of 27 July 2026

1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).

low confidence · 76.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Juvenile nasopharyngeal angiofibroma" OR "juvenile nasopharyngeal angiofibroma (disease)" OR "nasopharyngeal angiofibroma" OR "nasopharyngeal juvenile angiofibroma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Juvenile nasopharyngeal angiofibroma" OR "juvenile nasopharyngeal angiofibroma (disease)" OR "nasopharyngeal angiofibroma" OR "nasopharyngeal juvenile angiofibroma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: JNA

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1581) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T12:15:56.986Z